Mitoxantrone liposome combo for high-risk multiple myeloma
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests a liposomal form of mitoxantrone combined with other drugs for people with aggressive multiple myeloma (high-risk or spread outside the bone). The goal is to see if this approach helps control the cancer better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have high-risk multiple myeloma (with certain genetic changes) or myeloma that has spread outside the bone marrow (extramedullary).
- You are between 18 and 70 years old.
- You are well enough to do daily activities with little to no help (ECOG score 0–2).
- You have a measurable sign of myeloma, such as a tumor >1 cm or specific proteins in blood/urine.
- Your blood counts (neutrophils, platelets, hemoglobin) are above certain safe levels.
- You do not have serious heart problems, active hepatitis B or C, HIV, or uncontrolled infections.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of four medicines (isatuximab, bortezomib, lenalidomide, dexamethasone) for people with newly diagnosed high-risk multiple myeloma who are not having a stem cell transplant. The goal is to see if this combination can better control the disease and improve outcomes.
This study tests a combination of three drugs (belantamab mafodotin, bortezomib, and dexamethasone) for people with multiple myeloma who also have moderate liver problems. The goal is to see if this combination is safe and works well for them.
This trial tests a combination of study drugs as the first treatment for newly diagnosed multiple myeloma, followed by maintenance based on your risk and response. It aims to improve outcomes while allowing some patients to postpone or avoid a stem cell transplant.
This trial tests a new drug called linvoseltamab combined with other cancer treatments for people with multiple myeloma that has stopped responding to standard therapies. It may be an option if you have already tried several treatments and are looking for a new approach.
This trial tests a combination of three drugs (mitoxantrone liposome, cytarabine, and venetoclax) for people with AML that has returned or not responded to treatment. The goal is to see if this combination can help control the leukemia.
This clinical trial tests a combination of three drugs: a liposomal form of mitoxantrone (a type of chemotherapy), cytarabine (another chemo drug), and venetoclax (a targeted therapy). The goal is to see if this combination is safe and works well for older adults (ages 60-70) who have just been diagnosed with AML and cannot have standard intensive chemotherapy.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.